RE:New Press Release - Theralase(R) Announces Appointment of New Independent Director This nomination is another step announcing an onward and upward transformative movement over time. Clearly, others steps are coming.
Interesting profile:
- extensive big pharma,
- served, for over a decade, in global and regional leadership roles at Amgen, Sanofi, GlaxoSmithKline and AstraZeneca, in the United States, Europe, United Kingdom, Middle East and North Africa,
- specialized executive master's degree in strategy and management from ESSEC Business School in Paris, a master's degree in international policy and health economics from the London School of Economics, a corporate governance certification from Columbia Business School and finance certification from Harvard Business School,
- board of directors of Hepion Pharmaceuticals; a US public biotech (NASDAQ: HEPA),
- employed in executive and non-executive roles for: Cytovia Therapeutics, Steba Biotech and Immune Pharmaceuticals,
Based on this latest interim clinical data, the Company is commencing to actively explore international partnering, licensing and distribution opportunities for our cancer targeting PDC, Ruvidar™